ALN-HTT02 Updates Presented at the CHDI Foundation’s Annual Huntington’s Disease Therapeutics Conference

29 Feb, 2024 ALN-HTT02 Updates Presented at the CHDI Foundation’s Annual Huntington’s Disease Therapeutics Conference

New preclinical data for ALN-HTT02—an RNAi therapeutic development candidate targeting huntingtin (HTT) for Huntington’s disease (HD)—were presented during the CHDI Foundation’s 19th Annual Huntington’s Disease Therapeutics Conference in Palm Springs, CA . Additional data were presented on the emerging tolerability profile of the underlying C16-siRNA central nervous system delivery platform, highlighting potential differences with antisense oligonucleotides (ASOs) in development for HD.

Cantley, et al. “A New Approach to HTT-Lowering Using C16-siRNA Conjugates”
De Angelis, et al. “Emerging Tolerability Profiles of C16-siRNA Conjugates for CNS Delivery”